ClinicalTrials.gg
CompletedNCT01231659Updated Mar 26, 2021Results posted

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of Everolimus and Letrozole in Postmenopausal Women, Locally Advanced Metastatic Breast Cancer and Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.

Enrollment
36th of 78
72 · median 55
Started
2011
with 2 others
Phase 2
40 of 78
3 open now
Registered
28th of 78
by date
Lead sponsor
14 of 78
Novartis Pharmaceuticals

Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 36th largest by enrollment, is one of 3 that started in 2011, is one of 40 in phase 2, and was the 28th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing everolimus in Breast Neoplasms, or all of them as a file.
02

Study summary

This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or Examestane.

There were no treatments specifically approved after recurrence or progression on AIs. Available options, based on common clinical practice and several treatment guidelines (e.g. NCCN treatment guidelines 2008), included fulvestrant.

Combining RAD001 with letrazole was a rational approach to the treatment of advanced Brest Cancer, offering the potential for inhibition of tumor cell growth\ proliferation and anti angiogenesis while at the same time potentially preventing the development of letrazole resistance.

Read the detailed description

Screening Period:

Postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer whose disease was refractory to hormonal therapy and had a documented recurrence or progression on last therapy for their breast cancer with either tamoxifen, anastrozole, letrozole, fulvestrant or exemestan were screened for eligibility within 28 days prior to treatment Day 1.

Treatment Period:

Patients started receiving everolimus (10 mg daily oral dose) combined with letrozole (2.5 mg daily oral dose) tablets from treatment Day 1. Study treatment continued until disease progression, intolerable toxicity or consent withdrawal. Dose adjustment (reduction, interruption or possible dose re-escalation to starting dose) could be done based on the safety findings. Tumor assessments were performed every 12 weeks until disease progression. In order to confirm response at least four weeks after first observation, additional scans to determine a complete response (CR) or partial response (PR) or stable disease (SD) were performed. Patients were followed for safety until 28 days after study treatment discontinuation.

Post Treatment Follow up for Survival:

Patients were followed for survival every 3 months for up to 3 years. Survival information could be obtained via phone and information was documented in the source documents.

03

Conditions studied

  • Postmenopausal Women
  • Locally Advanced Metastatic Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

Keywords

  • RAD001 (Everolimus)
  • Letrozole
  • Breast cancer
  • Metastatic Breast cancer
  • Estrogen receptor positive
  • Failure of Tamoxifen
  • Anastrozole or Examestane
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with estrogen receptor positive locally advanced or breast cancer after documented recurrence or progression on Tamoxifen, Anastrozole or Examestane.

    • disease to hormonal therapy is defined as:

      1. Recurrence while on, or within 12 month of end of, treatment with Tamoxifen , Anastrozole, or Exemestane.
      2. Recurrence while on, or within 24 month of end of, adjuvant treatment with Letrozole.
      3. Progression while on Tamoxifen, Anastrozole or Exemestane treatment for locally advanced or metastatic breast cancer.

Exclusion criteria

Exclusion Criteria:

  • Prior use of chemotherapy and letrozole for Advanced Breast Cancer and mTOR inhibitors as the last anticancer treatment prior to study entry.
  • Patients must have radiological evidence of recurrence or progression on last therapy prior to study entry.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Everolimus + Letrozole

    All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.

    Drug: Everolimus · Drug: Letrozole

Interventions

  • Everolimus 10 mg (2 tablets of 5 mg) once daily

    Also known as: RAD001

  • Letrozole 2.5 mg once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. Only descriptive statistics.

    Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 15 months

Secondary outcomes

  1. Median Time to Progression-Free Survival (PFS)

    Progression Free Survival (PFS) was defined as the time from the date of study entry to the date of first documented tumor progression or death from any cause, whichever occurred first. If a patient did not have an event, PFS was censored at the last date of tumor assessment. For patients with measurable disease at baseline, progression was determined according to the RECIST 1.0 criteria. Only descriptive analysis done.

    Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 66 months

  2. Median Time to Overall Survival (OS)

    Overall Survival (OS) was defined as the time from the date of study entry to date of death due to any cause. If a death had not observed by the date of analysis, then OS was censored at the date of last contact. Distribution of OS was estimated using the Kaplan Meier method. The median OS along with 95% CI was presented.

    Time frame: From Date of randomization up to approximately 66 months

  3. Disease Control Rate (DCR)

    Disease Control Rate (DCR) was defined as the proportion of patients whose best overall response was either: Complete Response (CR), Partial Response (PR) or Stable Disease (SD). Disease Control Rate was calculated only for patients with measurable disease at baseline and was summarized using descriptive statistics.

    Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 66 months

  4. Long-term Safety and Tolerability

    The assessment of safety was based mainly on the frequency of AEs and on the number of laboratory values that fell outside of pre-determined ranges. Other safety data (e.g. ECG, vital signs) were considered as appropriate. Only descriptive analysis done.

    Time frame: From Date of first dose up to approximately 66 months

07

Results

Posted Mar 26, 2021

Participant flow

This study was conducted in 7 study centers in Israel.

Participant flow — Overall Study
MilestoneEverolimus + Letrozole
Started72
Per protocol (pp) set72
Safety set72
Completed0
Not completed72
Withdrew: Adverse event9
Withdrew: Disease progression48
Withdrew: Death2
Withdrew: Patient refused to complete study visit1
Withdrew: Other protocol defined criteria12

Outcome measures

PrimaryPercentage of Participants With Overall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. Only descriptive statistics.

Time frame:
From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 15 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Overall Response Rate (ORR)
Percentage of ParticipantsEverolimus + Letrozole
Percentage of Participants With Overall Response Rate (ORR)37.2
SecondaryMedian Time to Progression-Free Survival (PFS)

Progression Free Survival (PFS) was defined as the time from the date of study entry to the date of first documented tumor progression or death from any cause, whichever occurred first. If a patient did not have an event, PFS was censored at the last date of tumor assessment. For patients with measurable disease at baseline, progression was determined according to the RECIST 1.0 criteria. Only descriptive analysis done.

Time frame:
Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 66 months
Reported as:
Median · Months
Median Time to Progression-Free Survival (PFS)
MonthsEverolimus + Letrozole
Median Time to Progression-Free Survival (PFS)9.0 (0.2 to 59.6)
SecondaryMedian Time to Overall Survival (OS)

Overall Survival (OS) was defined as the time from the date of study entry to date of death due to any cause. If a death had not observed by the date of analysis, then OS was censored at the date of last contact. Distribution of OS was estimated using the Kaplan Meier method. The median OS along with 95% CI was presented.

Time frame:
From Date of randomization up to approximately 66 months
Reported as:
Median · Months
Median Time to Overall Survival (OS)
MonthsEverolimus + Letrozole
Median Time to Overall Survival (OS)22.3 (0.2 to 65.0)
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) was defined as the proportion of patients whose best overall response was either: Complete Response (CR), Partial Response (PR) or Stable Disease (SD). Disease Control Rate was calculated only for patients with measurable disease at baseline and was summarized using descriptive statistics.

Time frame:
From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 66 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsEverolimus + Letrozole
Disease Control Rate (DCR)85.7 (74.6 to 93.3)
SecondaryLong-term Safety and Tolerability

The assessment of safety was based mainly on the frequency of AEs and on the number of laboratory values that fell outside of pre-determined ranges. Other safety data (e.g. ECG, vital signs) were considered as appropriate. Only descriptive analysis done.

Time frame:
From Date of first dose up to approximately 66 months
Reported as:
Number · Participants
Long-term Safety and Tolerability
ParticipantsEverolimus + Letrozole
AEs - All72
AEs - Grade 339
AEs - Grade 47
Post-hocAll Collected Deaths

On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of 2002 days (treatment duration ranged from 1 to 1974 days). Deaths post treatment survival follow up were collected after the on- treatment period, up to approximately 2092 days. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.

Time frame:
up to 2002 days (on-treatment), up to approximately 2092 days (study duration)
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsEverolimus + Letrozole
On-treatment deaths2
Post-treatment deaths50
All deaths52

Adverse events

Collected over Adverse Events were collected from First Patient First Treatment (FPFT) up to 28 days after study drug discontinuation, for a maximum duration of 2002 days (treatment duration ranged from 1 to 1974 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus + Letrozole2/72 (2.8%)26/72 (36.1%)71/72 (98.6%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventEverolimus + Letrozole
AnaemiaBlood and lymphatic system disorders5/72
VomitingGastrointestinal disorders3/72
PyrexiaGeneral disorders3/72
Disease progressionGeneral disorders2/72
CellulitisInfections and infestations2/72
Acute kidney injuryRenal and urinary disorders2/72
DyspnoeaRespiratory, thoracic and mediastinal disorders2/72
Cardiac arrestCardiac disorders1/72
Cardiac failure congestiveCardiac disorders1/72
HypercalcaemiaEndocrine disorders1/72
Most frequent other events
Showing 10 of 68
Most frequent other events
EventEverolimus + Letrozole
FatigueGeneral disorders49/72
StomatitisGastrointestinal disorders27/72
Decreased appetiteMetabolism and nutrition disorders24/72
Mucosal inflammationGeneral disorders23/72
CoughRespiratory, thoracic and mediastinal disorders23/72
HeadacheNervous system disorders22/72
RashSkin and subcutaneous tissue disorders22/72
AnaemiaBlood and lymphatic system disorders21/72
DiarrhoeaGastrointestinal disorders21/72
Weight decreasedInvestigations21/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus + Letrozole
Mean61.7 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus + Letrozole
Female72
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus + Letrozole
Caucasian72
08

Study locations

7 sites
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Kfar Saba, 4428164, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Rehovot, 76100, Israel
  • Novartis Investigative Site
    Tel Aviv, 62439, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
09

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Nov 2012, 15 months.

Results were first posted in Mar 2021, 8 years 4 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 15 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2010
First posted
Nov 1, 2010
StartActual
Aug 9, 2011
Primary completionActual
Nov 20, 2012
CompletionActual
Apr 30, 2017
Results first posted
Mar 26, 2021
Last update
Mar 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01231659
Responsible party
Sponsor
First posted
Nov 1, 2010
Start date
Aug 9, 2011
Primary completion
Nov 20, 2012
Completion
Apr 30, 2017
Results posted
Mar 26, 2021
Last update
Mar 26, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Letrozole

Start the discussion